Article | October 1, 2021

What Big CROs Don't Want You To Know About Staffing Scalability For Phase III Studies

By Joseph Arcangelo, inSeption Group

iStock-159091257 PS

There seems to be a conventional wisdom stating a Phase III study should be handled by a large CRO. After all, large CROs generally have the resources on-hand to staff such a study within the sponsor’s ambitious timeline. In fact, while this model might be advantageous for expansive studies in non-critical indications, it usually fails to meet the personnel needs of sponsors executing Phase III studies in critical indications, ranging from oncology and neurological disorders to development of orphan drugs.

Understanding the pros and cons when deciding between a large CRO and a more niche partner requires an examination of all factors affecting scale-up to a Phase III study: therapeutic area, the dynamics of business operations between large and small organizations, how such organizations scale up employee numbers, and more.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: